ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Oncology"

  • Abstract Number: 0125 • ACR Convergence 2023

    Decreasing Ischemic Heart Disease, but Increasing Cancer Among the Underlying Causes of Death in Decedents with Lupus Nephritis

    snehin Rajkumar1 and Ram Singh2, 1University of California Los Angeles, Irvine, CA, 2UCLA David Geffen School of Medicine, Los Angeles, CA

    Background/Purpose: Patients with lupus nephritis may die of active systemic lupus erythematosus (SLE) disease, end-stage renal disease (ESRD) and its complications as well as of…
  • Abstract Number: 1054 • ACR Convergence 2023

    Immune Checkpoint Inhibitor Induced Polymyalgia Rheumatica Demonstrates a Similar Scintigraphic Appearance to Classical Polymyalgia Rheumatica on 18F-Fluorodeoxyglucose PET/CT

    David Liew1, Aurora Poon1, Christopher McMaster2, Russell Buchanan1, Victor Yang1, Andrew Scott1 and Claire Owen3, 1Austin Health, Heidelberg, Australia, 2Austin Health, Pascoe Vale South, Australia, 3Austin Health, Malvern East, Australia

    Background/Purpose: Of the rheumatic immune-related adverse events that follow immune checkpoint inhibitor (ICI) cancer immunotherapy, de novo PMR-like episodes without inflammatory arthritis (ICI-PMR) appear to…
  • Abstract Number: 1056 • ACR Convergence 2023

    Immune Checkpoint Inhibitor Rechallenge in Patients Who Previously Experienced Immune-Related Inflammatory Arthritis: A Multicenter Observational Study

    Alexandra Ladouceur1, Gael Mouterde2, Alice TISON3, Samuel Bitoun4, Sorilla Mary-Prey5, Caroline Dutriaux6, Emilie Gerard5, Anne Pham-Ledard5, Marie Beylot-Barry5, Maeva Zysman5, Rémi Veillon5, Charlotte Domblides7, Amaury Daste7, Marine Gross-Goupil7, Baptiste Sionneau7, Félix Lefort7, Mathieu Larroquette7, Thomas Barnetche8, Christophe Richez9, Marie-Elise Truchetet8, Thierry Schaeverbebke10 and Marie Kostine8, 1Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, 2CHU Lapeyronie, Montpellier, France, 3CHU de la Cavale Blanche, Brest, France, 4Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, FHU CARE, Inserm UMR 1184, Paris, France, 5Department of Dermatology, Bordeaux University Hospital, Bordeaux, France, 6CHU-Bordeaux, Bordeaux, France, 7Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France, 8Bordeaux University Hospital, Bordeaux, France, 9Université de Bordeaux, Bordeaux, France, 10University Hospital of Bordeaux, Bordeaux, France

    Background/Purpose: Immune checkpoint inhibitors (ICI) improve overall survival in many cancer patients by activating their immune system. However, they can cause off-target immune-related adverse events…
  • Abstract Number: 1057 • ACR Convergence 2023

    Melanoma and Combination Immune Checkpoint Inhibitors Are More Clearly Associated with the Development of Chronic Inflammatory Arthritis Than Pre-existing Autoimmune Disease: A Cross-Sectional Study of Administrative Health Data

    Alexandra Ladouceur1, Marie Hudson2, Hassan Behlouli3, Jeffrey Curtis4, Louise Pilote3 and Sasha Bernatsky3, 1Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, 2McGill University, Montréal, QC, Canada, 3Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 4University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Immune checkpoint inhibitors (ICIs) improve survival in many malignancies1, by augmenting the immune system's anti-tumor response. However, ICI can result in immune-related adverse events…
  • Abstract Number: 1058 • ACR Convergence 2023

    Resolution of Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis While Maintaining Active Treatment with Checkpoint Inhibitors

    Alexandra Ladouceur1, Thomas Barnetche2, Sorilla Mary-Prey3, Caroline Dutriaux4, Emilie Gerard3, Anne Pham-Ledard3, Marie Beylot-Barry3, Maeva Zysman3, Rémi Veillon3, Charlotte Domblides5, Amaury Daste5, Marine Gross-Goupil5, Baptiste Sionneau5, Félix Lefort5, Mathieu Larroquette5, Christophe Richez6, Marie-Elise Truchetet2, Thierry Schaeverbebke7 and Marie Kostine2, 1Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, 2Bordeaux University Hospital, Bordeaux, France, 3Department of Dermatology, Bordeaux University Hospital, Bordeaux, France, 4CHU-Bordeaux, Bordeaux, France, 5Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France, 6Université de Bordeaux, Bordeaux, France, 7University Hospital of Bordeaux, Bordeaux, France

    Background/Purpose: Immune checkpoint inhibitors (ICI) are a revolutionary treatment that boost a patient's own immune system to fight cancer. However, activation of the immune system…
  • Abstract Number: 1074 • ACR Convergence 2023

    Baseline Clinical Features, but Not Shared Epitope or HLA B27, Predict Severe Outcomes for Immune Checkpoint Inhibitor-induced Inflammatory Arthritis

    Laura Cappelli1, omer Kamal2, Michelle Jones3, Clifton Bingham4 and Ami Shah5, 1Johns Hopkins School of Medicine, Baltimore, MD, 2St. Agnes Hospital, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4Johns Hopkins University, Baltimore, MD, 5Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD

    Background/Purpose: Immune checkpoint inhibitors (ICI) can cause inflammatory arthritis (IA) of varying severity. Many patients with ICI-IA require immunosuppression beyond corticosteroids, but there is no…
  • Abstract Number: 2138 • 2019 ACR/ARP Annual Meeting

    Rheumatic Immune-related Adverse Effects from Checkpoint Inhibitor Immunotherapy in Patients with Solid Tumors in a Latin American Population

    Alain Sánchez-Rodríguez1, Elina Alexandra Rodriguez-Melendez 2, Alonso Turrent-Carriles 3, Paola Bermúdez-Bermejo 3, josé Fabián Martínez-Herrera 2 and Raquel Gerson-Cwilich 2, 1Hospital General de Mexico, Mexico City, Distrito Federal, Mexico, 2ABC Medical Center, Oncology Department, Ciudad de Mexico, Distrito Federal, Mexico, 3ABC Medical Center, Rheumatology Department, Ciudad de Mexico, Distrito Federal, Mexico

    Background/Purpose: Cancer immunotherapy is a newly-approved approach in the management of advanced malignancies. Immune checkpoint inhibitors (ICIs) are the most commonly used type of cancer…
  • Abstract Number: 364 • 2018 ACR/ARHP Annual Meeting

    Elevated sCD40L As a Predictive Biomarker of Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors

    Nicholas Meti1, Khashayar Esfahani1,2, Ines Colmegna1,3, Marvin J. Fritzler4, Nathalie A. Johnson1,5, Ciriaco Piccirillo1,6, Wilson H. Miller Jr.1,2 and Marie Hudson1,7, 1Department of Medicine, McGill University, Montreal, QC, Canada, 2Department of Oncology, McGill University, Jewish General Hospital, Rossy Cancer Network, Montreal, QC, Canada, 3Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada, 4Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 5Division of Hematology, Jewish General Hospital, Montreal, QC, Canada, 6Department of Microbiology & Immunology, McGill University, Montreal, QC, Canada, 7Division of Rheumatology, Jewish General Hospital, Montreal, QC, Canada

    Background/Purpose: The clinical use of immune checkpoint inhibitors (ICI) has led to outstanding clinical outcomes in previously refractory cancers, but ICI have also been associated…
  • Abstract Number: 1914 • 2018 ACR/ARHP Annual Meeting

    Rheumatic Syndromes Associated with Immune-Checkpoint Inhibitors: A Single-Center Cohort of 61 Patients

    Michael Richter1, Cynthia S. Crowson2, Lisa Kottschade3, Heidi Finnes3, Svetomir N. Markovic4 and Uma Thanarajasingam5, 1Internal Medicine, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Oncology, Mayo Clinic, Rochester, MN, 4Department of Medicine and Oncology, Mayo Clinic, Rochester, MN, 5Department of Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose: Rheumatologists are increasingly called upon to manage the autoimmune side effects of immune-checkpoint inhibitors (ICIs). However, these new entities are poorly understood and treatment…
  • Abstract Number: 1880 • 2017 ACR/ARHP Annual Meeting

    Cancer Immunotherapy in Patients with Preexisting Rheumatologic Disease: The Mayo Clinic Experience

    Michael Richter1, Olga Pinkston2, Lisa Kottschade3, Heidi Finnes3, Svetomir N. Markovic4 and Uma Thanarajasingam5, 1Internal Medicine, Mayo Clinic, Rochester, MN, 2Rheumatology, Mayo Clinic Florida, Jacksonville, FL, 3Oncology, Mayo Clinic, Rochester, MN, 4Department of Medicine and Oncology, Mayo Clinic, Rochester, MN, 5Division of Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose: Immune checkpoint inhibitors have revolutionized the treatment of advanced malignancies. By blocking T-cell inhibition these drugs result in immune targeting of tumor cells and…
  • « Previous Page
  • 1
  • 2
  • 3
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology